MedTrace Logo

Study of Elobixibat (A3309) in Patients With Chronic Idiopathic Constipation

NCT01007123 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2017-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with chronic idiopathic constipation.

Conditions

Interventions

DRUG

A3309

A3309 in three different dosage levels or placebo once daily for the duration of the study

Sponsors & Collaborators

  • Albireo

    lead INDUSTRY

Principal Investigators

  • Hans Graffner, MD · Albireo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007123 on ClinicalTrials.gov